Investor Alert

Market Pulse Archives

March 19, 2020, 3:25 p.m. EDT

Bayer donates chloroquine to U.S., to seek emergency use as COVID-19 treatment

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Bayer AG ADR (BAYRY)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

U.S. listed shares of Bayer AG /zigman2/quotes/203424967/delayed BAYRY -0.96% rose 3% in trading on Thursday afternoon after it said it had donated three million tablets of Resochin, a chloroquine product, to the U.S. The German drugmaker said that it is seeking an emergency use authorization for the drug in the U.S., where it is not approved. Health care providers in countries like China and France have been using chloroquine-based therapies to treat COVID-19 patients as there are no proven treatments for the disease. At a news conference on Thursday, President Donald Trump talked up use of the antimalaria drug to treat patients who have the novel coronavirus, and FDA commissioner Stephen Hahn said that while chloroquine has been approved for other indications, it would still need to go through clinical trials. Bayer's stock is down 34% year-to-date, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.06% has dropped 25%.

US : U.S.: OTC
$ 16.46
-0.16 -0.96%
Volume: 648,446
Aug. 7, 2020 3:59p
P/E Ratio
Dividend Yield
Market Cap
$64.82 billion
Rev. per Employee
+2.12 +0.06%
Volume: 2.28B
Aug. 7, 2020 5:10p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.